Evaluation of a Novel Oral Anti-Tumor Agent in Patients with Metastatic or Locally Advanced Solid Tumors Lacking Standard Therapeutic Options

The primary objective of this clinical trial is to evaluate the efficacy and safety of a novel peroral anti-tumor treatment in patients with **metastatic** or locally advanced solid tumors. These tumors include those of the lung, head and neck, colon, stomach, esophagus, breast, ovary, and/or fallopian tube, as well as primary peritoneal high-grade serous carcinoma. This study is particularly relevant for patients for whom no standard therapy exists or for whom standard therapy has failed. The clinical relevance of this trial lies in its potential to provide a new therapeutic option for patients with limited treatment alternatives.

The clinical trial involves participants diagnosed with **metastatic or locally advanced solid tumors** for which no standard therapy exists or standard therapy has failed. These tumors include those of the lung, head and neck, colon, stomach, esophagus, breast, ovary, and/or fallopian tube, as well as primary peritoneal high-grade serous carcinoma. The study population comprises both male and female subjects, with an age range that includes adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate a novel peroral anti-tumor treatment in patients with **metastatic or locally advanced solid tumors** for which no standard therapy exists or standard therapy has failed. This includes tumors of the lung, head and neck, colon, stomach, esophagus, breast, ovary, and/or fallopian tube or primary peritoneal high-grade serous carcinoma. The trial is structured as a Phase 1 study, which is typically focused on assessing the safety, tolerability, and pharmacokinetics of the investigational treatment. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is June 1, 2023, with an anticipated end date of December 31, 2026, indicating a total trial duration of approximately three and a half years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational treatment or a control. Regular follow-up visits will be scheduled to monitor the participants' health, treatment response, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will occur at the conclusion of the treatment period, where final assessments will be conducted to evaluate the overall outcomes of the trial.

The expected length of participant involvement will vary depending on individual response to treatment and the occurrence of any adverse events. Participants may be withdrawn from the study early if they experience significant adverse effects, if the disease progresses, or if they choose to withdraw consent. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

No specific details regarding the assessment of efficacy in the clinical trial are provided in the available data. The information does not include parameters or endpoints used to evaluate efficacy, nor does it specify the methods, schedule, or tools for measuring, collecting, and analyzing efficacy parameters. The trial is identified as a Phase 1 study, with an estimated recruitment start date of June 1, 2023, and an estimated end date of December 31, 2026. Further details on efficacy assessment are not available in the provided data.